{"id":26735,"date":"2024-01-19T15:12:26","date_gmt":"2024-01-19T20:12:26","guid":{"rendered":"https:\/\/myeloma.ca\/?p=26735"},"modified":"2024-01-19T15:14:07","modified_gmt":"2024-01-19T20:14:07","slug":"lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/","title":{"rendered":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada!\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un<a href=\"https:\/\/health-products.canada.ca\/noc-ac\/nocInfo?no=32309&amp;lang=fre\" target=\"_blank\" rel=\"noreferrer noopener\"> avis de conformit\u00e9 avec conditions <\/a>(AC avec conditions) pour elranatamab (Elrexfio).\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un inhibiteur du prot\u00e9asome, un agent immunomodulateur et un anticorps monoclonal anti-CD38.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cliquez ici pour consulter les <a href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/info?code=103201&amp;lang=fre\" target=\"_blank\" rel=\"noreferrer noopener\">renseignements sur le produit (canada.ca)<\/a>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un avis de conformit\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio).\u00a0 Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[88,53],"tags":[],"class_list":["post-26735","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-evenement"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/26735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=26735"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/26735\/revisions"}],"predecessor-version":[{"id":26737,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/26735\/revisions\/26737"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=26735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=26735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=26735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}